Endogeny

Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants

Retrieved on: 
Monday, February 8, 2021

Existing investors agreed to exercise warrants for net proceeds of approximately $3 million.

Key Points: 
  • Existing investors agreed to exercise warrants for net proceeds of approximately $3 million.
  • The proceeds from the exercise of these warrants strengthen our balance sheet and based on our most recently reported financial results as of November 30, 2020 bring our pro-forma cash balance to approximately $10.4 million, stated Gregory Gorgas, Artelos President and Chief Executive Officer.
  • We intend to utilize this capital towards achieving milestones we believe have the potential to generate significant value for our shareholders.
  • Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways, including the endocannabinoid system.

DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03

Retrieved on: 
Tuesday, July 28, 2020

DURECT's lead candidate, DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator.

Key Points: 
  • DURECT's lead candidate, DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator.
  • It represents a new class of therapeutics with a unique mechanism of action.
  • DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs.
  • Further information regarding these and other risks is included in DURECT's Form 10-Q filed on May 11, 2020 under the heading "Risk Factors."

Global Endogenous Cushing's Syndrome Insights Report 2020 - Clinical Development Scenario, Growth Prospects and Pipeline Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020

Endogenous Cushing's Syndrome Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Endogenous Cushing's Syndrome market.

Key Points: 
  • Endogenous Cushing's Syndrome Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Endogenous Cushing's Syndrome market.
  • A detailed picture of the Endogenous Cushing's Syndrome pipeline landscape is provided, which includes the disease overview and Endogenous Cushing's Syndrome treatment guidelines.
  • The assessment part of the report embraces in-depth Endogenous Cushing's Syndrome commercial assessment and clinical assessment of the Endogenous Cushing's Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Endogenous Cushing's Syndrome.